Cargando…

Evaluating IL-21 as a Potential Therapeutic Target in Crohn's Disease

BACKGROUND AND AIM: Interleukin-21 (IL-21) is primarily a T cell-derived cytokine; it is upregulated in patients with Crohn's Disease (CD) and could be a potential new therapeutic target in CD. METHODS: In human material, IL-21 and IL-21R expression was investigated by in situ hybridization (IS...

Descripción completa

Detalles Bibliográficos
Autores principales: Holm, Thomas Lindebo, Tornehave, Ditte, Søndergaard, Henrik, Kvist, Peter Helding, Sondergaard, Bodil-Cecilie, Hansen, Lene, Hermit, Mette Brunsgaard, Holgersen, Kristine, Vergo, Sandra, Frederiksen, Klaus Stensgaard, Haase, Claus, Lundsgaard, Dorthe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5914125/
https://www.ncbi.nlm.nih.gov/pubmed/29849593
http://dx.doi.org/10.1155/2018/5962624
_version_ 1783316654936031232
author Holm, Thomas Lindebo
Tornehave, Ditte
Søndergaard, Henrik
Kvist, Peter Helding
Sondergaard, Bodil-Cecilie
Hansen, Lene
Hermit, Mette Brunsgaard
Holgersen, Kristine
Vergo, Sandra
Frederiksen, Klaus Stensgaard
Haase, Claus
Lundsgaard, Dorthe
author_facet Holm, Thomas Lindebo
Tornehave, Ditte
Søndergaard, Henrik
Kvist, Peter Helding
Sondergaard, Bodil-Cecilie
Hansen, Lene
Hermit, Mette Brunsgaard
Holgersen, Kristine
Vergo, Sandra
Frederiksen, Klaus Stensgaard
Haase, Claus
Lundsgaard, Dorthe
author_sort Holm, Thomas Lindebo
collection PubMed
description BACKGROUND AND AIM: Interleukin-21 (IL-21) is primarily a T cell-derived cytokine; it is upregulated in patients with Crohn's Disease (CD) and could be a potential new therapeutic target in CD. METHODS: In human material, IL-21 and IL-21R expression was investigated by in situ hybridization (ISH) and immunohistochemistry (IHC) in noninflammatory bowel disease (non-IBD) controls and patients with CD. The pathologic role of IL-21 was examined in murine models of T cell-dependent and T cell-independent colitis, either with a neutralizing monoclonal antibody against IL-21 or with the transfer of CD4(+)CD45RB(high)IL-21R(−/−) T cells. Colonic pathology was examined by endoscopy, histopathology, IHC, ELISA, and Luminex. RESULTS: In the human intestine, IL-21 and IL-21R mRNA and protein-expressing cells were observed in the mucosa, in lymphoid aggregates of submucosa in non-IBD controls, and in lymphoid aggregates of muscularis externa in patients with CD. IL-21 expression was most abundant in germinal centers (GCs) of the lymphoid aggregates, and IL-21R expression assessed semiquantitatively, was significantly higher in patients with CD compared to non-IBD controls. Following prophylactic and interventive anti-IL-21 mAb treatment in the adoptive transfer (AdTr) model, clinical and pathological parameters were significantly reduced. The most persistent finding was a reduction in colonic infiltrating neutrophils. As well, Rag2(−/−) mice receiving CD4(+)CD45RB(high)IL-21R(−/−) T cells developed less severe colitis compared to Rag2(−/−) mice receiving CD4(+)CD45RB(high)IL-21R(+/+) T cells. No effect of reduced IL-21 signalling was observed in T cell-independent colitis. CONCLUSION: Our study shows that patients with CD have significant expression of IL-21 and IL-21R in the gut. As well, we show that neutralization of IL-21 in experimental T cell-driven colitis is associated with a reduction in clinical and pathological findings. This amelioration seems to be associated with a reduction in colon-infiltrating neutrophils.
format Online
Article
Text
id pubmed-5914125
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-59141252018-05-30 Evaluating IL-21 as a Potential Therapeutic Target in Crohn's Disease Holm, Thomas Lindebo Tornehave, Ditte Søndergaard, Henrik Kvist, Peter Helding Sondergaard, Bodil-Cecilie Hansen, Lene Hermit, Mette Brunsgaard Holgersen, Kristine Vergo, Sandra Frederiksen, Klaus Stensgaard Haase, Claus Lundsgaard, Dorthe Gastroenterol Res Pract Research Article BACKGROUND AND AIM: Interleukin-21 (IL-21) is primarily a T cell-derived cytokine; it is upregulated in patients with Crohn's Disease (CD) and could be a potential new therapeutic target in CD. METHODS: In human material, IL-21 and IL-21R expression was investigated by in situ hybridization (ISH) and immunohistochemistry (IHC) in noninflammatory bowel disease (non-IBD) controls and patients with CD. The pathologic role of IL-21 was examined in murine models of T cell-dependent and T cell-independent colitis, either with a neutralizing monoclonal antibody against IL-21 or with the transfer of CD4(+)CD45RB(high)IL-21R(−/−) T cells. Colonic pathology was examined by endoscopy, histopathology, IHC, ELISA, and Luminex. RESULTS: In the human intestine, IL-21 and IL-21R mRNA and protein-expressing cells were observed in the mucosa, in lymphoid aggregates of submucosa in non-IBD controls, and in lymphoid aggregates of muscularis externa in patients with CD. IL-21 expression was most abundant in germinal centers (GCs) of the lymphoid aggregates, and IL-21R expression assessed semiquantitatively, was significantly higher in patients with CD compared to non-IBD controls. Following prophylactic and interventive anti-IL-21 mAb treatment in the adoptive transfer (AdTr) model, clinical and pathological parameters were significantly reduced. The most persistent finding was a reduction in colonic infiltrating neutrophils. As well, Rag2(−/−) mice receiving CD4(+)CD45RB(high)IL-21R(−/−) T cells developed less severe colitis compared to Rag2(−/−) mice receiving CD4(+)CD45RB(high)IL-21R(+/+) T cells. No effect of reduced IL-21 signalling was observed in T cell-independent colitis. CONCLUSION: Our study shows that patients with CD have significant expression of IL-21 and IL-21R in the gut. As well, we show that neutralization of IL-21 in experimental T cell-driven colitis is associated with a reduction in clinical and pathological findings. This amelioration seems to be associated with a reduction in colon-infiltrating neutrophils. Hindawi 2018-04-10 /pmc/articles/PMC5914125/ /pubmed/29849593 http://dx.doi.org/10.1155/2018/5962624 Text en Copyright © 2018 Thomas Lindebo Holm et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Holm, Thomas Lindebo
Tornehave, Ditte
Søndergaard, Henrik
Kvist, Peter Helding
Sondergaard, Bodil-Cecilie
Hansen, Lene
Hermit, Mette Brunsgaard
Holgersen, Kristine
Vergo, Sandra
Frederiksen, Klaus Stensgaard
Haase, Claus
Lundsgaard, Dorthe
Evaluating IL-21 as a Potential Therapeutic Target in Crohn's Disease
title Evaluating IL-21 as a Potential Therapeutic Target in Crohn's Disease
title_full Evaluating IL-21 as a Potential Therapeutic Target in Crohn's Disease
title_fullStr Evaluating IL-21 as a Potential Therapeutic Target in Crohn's Disease
title_full_unstemmed Evaluating IL-21 as a Potential Therapeutic Target in Crohn's Disease
title_short Evaluating IL-21 as a Potential Therapeutic Target in Crohn's Disease
title_sort evaluating il-21 as a potential therapeutic target in crohn's disease
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5914125/
https://www.ncbi.nlm.nih.gov/pubmed/29849593
http://dx.doi.org/10.1155/2018/5962624
work_keys_str_mv AT holmthomaslindebo evaluatingil21asapotentialtherapeutictargetincrohnsdisease
AT tornehaveditte evaluatingil21asapotentialtherapeutictargetincrohnsdisease
AT søndergaardhenrik evaluatingil21asapotentialtherapeutictargetincrohnsdisease
AT kvistpeterhelding evaluatingil21asapotentialtherapeutictargetincrohnsdisease
AT sondergaardbodilcecilie evaluatingil21asapotentialtherapeutictargetincrohnsdisease
AT hansenlene evaluatingil21asapotentialtherapeutictargetincrohnsdisease
AT hermitmettebrunsgaard evaluatingil21asapotentialtherapeutictargetincrohnsdisease
AT holgersenkristine evaluatingil21asapotentialtherapeutictargetincrohnsdisease
AT vergosandra evaluatingil21asapotentialtherapeutictargetincrohnsdisease
AT frederiksenklausstensgaard evaluatingil21asapotentialtherapeutictargetincrohnsdisease
AT haaseclaus evaluatingil21asapotentialtherapeutictargetincrohnsdisease
AT lundsgaarddorthe evaluatingil21asapotentialtherapeutictargetincrohnsdisease